SCHEMBL4604515

SCHEMBL4604515

Nc1ccc(Sc2ccccc2C(F)(F)F)cc1C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.49
MCL1 Q07820 2/20 0.49
LMNA P02545 2/20 0.49
HTT P42858 2/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
BCL2A1 Q16548 1/20 0.49
KEAP1 Q14145 1/20 0.43
CFTR P13569 1/20 0.42
KDM4E B2RXH2 4/20 0.41
KMT2A Q03164 2/20 0.41
GFER P55789 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
ALDH1A1 P00352 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
POLB P06746 1/20 0.41
THRB P10828 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4603431 0.80 DTYMK (0.57) MAPTLMNAHTTKDM4EKMT2A
SCHEMBL1143102 0.77 KDM4E (0.61) MAPTMCL1LMNAHTTTSHR
SCHEMBL8531244 0.76 POLB (0.53) MAPTLMNAHTTKDM4EKMT2A
SCHEMBL4605316 0.76 AKR1C3 (0.46) MCL1LMNABCL2A1KDM4EKMT2A
SCHEMBL5712968 0.76 TAS2R14 (0.36) MAPTLMNAHTTKDM4ERXFP1
Propionaldehyde SCHEMBL5712970 0.76 TAS2R14 (0.36) MAPTLMNAHTTKDM4EPTPN11
SCHEMBL22519100 0.73 MAPT (0.72) MAPTMCL1LMNAHTTTSHR
SCHEMBL11473055 0.73 LMNA (0.47) MAPTLMNAHTTKDM4EALDH1A1
SCHEMBL5886112 0.73 MAPT (0.40) MAPTMCL1LMNAHTTKDM4E
SCHEMBL9198998 0.72 KEAP1 (0.66) MAPTMCL1LMNAHTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
EP-1720825-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF Active Biotech AB (SE) 2006-11-15 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed
WO-2005075410-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF ACTIVE BIOTECH AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 MAPT 3698/4885MCL1 568/4885LMNA 4153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.